


Establishment of a Wave bioreactor scale-down model for process development and characterization studies

Intellectual Property Notice: Part of GE Healthcare's Life Sciences business was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company. Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva. All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information. For local office contact information, visit cytiva.com/contact

CY16288-04Sep20-PT



Bristol-Myers Squibb

Establishment of a Wave™ bioreactor scale-down model for process development and characterization studies

Sarwat F. Khattak, Sivakesava Sakhamuri, Ellen Lam, Xiaolin Liu, Zhengjian Li, and Steven Lee

Process Sciences-Upstream, Process Development Technical Operations, Bristol-Myers Squibb Company, Syracuse, NY

Introduction

The Wave™ Bioreactor system is typically applied to the inoculum train process. We evaluated the 10-L system as a scale-down model for production of a fusion protein by Chinese Hamster Ovary (CHO) cells. The Wavebag was operated in fed-batch mode and the results were compared to a 5-L stirred-tank bioreactor (STR).

The disposable technology allows faster turnaround and is simple to implement. Training, cleaning and validation are minimal for the system. This study investigated the feasibility of upstream characterization and development in a Wave™ bioreactor system¹.

Figure 1. Representation of a 5-L bioreactor system and Wave™ Bioreactor



Methodology

Wave™-specific :	Bioreactor-specific:
- Rocking speed (rpm)	- Mixing speed
- Rocking angle	- Sparge rate

Culture conditions for the Wave bioreactor

- Rocking speed	30 rpm
- Rocking angle	7°
- DO profile	not controlled
- pH setpoint	7.0 +/- 0.1
- Back pressure	Ambient
- Air flow rate	0.1 LPM
- pH control	% CO ₂ and caustic

Culture conditions for 5-L bioreactor

- DO profile	50%
- pH setpoint	7.0 +/- 0.05
- Back pressure	Ambient
- Bottom air flow rate	0.005 LPM
- Top air flow rate	0.050 LPM
- Mixing speed	180-200 rpm
- pH control	% CO ₂ and caustic

Two medias were evaluated:

1. Version 1 basal and feed media
2. Version 2 basal and feed media

Results- Version 1 Basal/Feed




Figure 2. Operating conditions critical for protein yield and quality. A) Viable cell density and pH profile B) pCO₂ and DO profile C) Protein Yield and Quality

Results- Version 2 Basal/Feed




Figure 3. Operating conditions critical for protein yield and quality. A) Viable cell density and pH profile B) pCO₂ and DO profile C) Protein Yield and Quality

Discussion

Although a lower peak VCD is achieved, the protein production is comparable to small-scale bioreactor production. Media changes were discernible in the Wave™ bioreactor suggesting that this technology is applicable for upstream characterization and development studies. Results were within the acceptable range defined for protein yield and quality.

The differences in VCD can be attributed to the pH deadband. Cell culture growth is significantly affected by pH control. Current technology for the Wave unit does not provide for fine pH control.

Significant differences were also seen in the DO profile (Figure 3b) which cannot be improved upon unless oxygen is delivered to the Wavebag™ (currently only air/CO₂).

Conclusions

Wave™ bioreactors operated in fed-batch mode can indicate changes in cell culture performance and produce similar results as seen in stirred-tank bioreactors. The technology can be applied in upstream development to quickly and easily evaluate media and process variable conditions. The results achieved in a Wave™ bioreactor system can be utilized for development and process characterization studies.

Future Work

- Optimization of pH control is critical for protein quality and cell growth. The current Wave™ bioreactor pH control has a deadband of 0.1 while in the bioreactors, a deadband of 0.05 is possible.
- Differences in pCO₂ and DO are critical parameters that cannot be adjusted in the current system.
- Higher peak VCD and IVCD can be achieved in the Wave bioreactor system with optimization of feeding strategy and improved pH control.

References

1. Singh, V. 1999. Disposable bioreactor for cell culture using wave-induced agitation. *Cytotechnology* 30:149-158.
2. http://wavebiotech.com/products/wave_bioreactor/system20/index.html#

Acknowledgments

We thank Erin McCormack, Nishish Dalal, Joseph Caiello and the Process Sciences Upstream group for laboratory assistance, and the Analytical Biochemistry group (BMS-Syracuse) for protein characterization.